Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.39 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2550326 | 0.86 | L3MBTL3 (0.46) | L3MBTL3MBTD1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1936310 | 0.86 | HSD11B1 (0.37) | L3MBTL3MBTD1L3MBTL1ALDH1A1 | |
| SCHEMBL2553841 | 0.84 | HRH3 (0.44) | L3MBTL3MBTD1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL65329 | 0.84 | HRH3 (0.47) | L3MBTL3L3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL8309136 | 0.84 | HSD11B1 (0.36) | L3MBTL3MBTD1L3MBTL1ALDH1A1 | |
| SCHEMBL4720502 | 0.81 | L3MBTL3 (0.42) | L3MBTL3MBTD1L3MBTL1TP53BP1L3MBTL4 | |
| SCHEMBL4334091 | 0.80 | L3MBTL3 (0.58) | L3MBTL3MBTD1L3MBTL1TP53BP1L3MBTL4 | |
| SCHEMBL2862492 | 0.80 | L3MBTL3 (0.58) | L3MBTL3MBTD1L3MBTL1TP53BP1L3MBTL4 | |
| SCHEMBL23089850 | 0.79 | HSD11B1 (0.46) | L3MBTL3MBTD1ALDH1A1 | |
| SCHEMBL31334651 | 0.79 | CHRM1 (0.45) | L3MBTL3MBTD1L3MBTL1ALDH1A1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | L3MBTL3 4412/4885MBTD1 1344/4885L3MBTL1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.